Question · asked by 1 review
Pregabalin vs placebo: Maintenance of initial therapeutic response of at least 30% pain intensity reduction over baseline and continued treatment at 13 or 26 weeks (equivalent to 'moderate benefit')
- Population
- adults with fibromyalgia enrolled in EERW studies
- Intervention
- Pregabalin
- Comparison
- placebo
- Outcome
- Maintenance of initial therapeutic response of at least 30% pain intensity reduction over baseline and continued treatment at 13 or 26 weeks (equivalent to 'moderate benefit')
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Pregabalin vs placebo Maintenance of initial therapeutic response of at least 30% pain intensity reduction over baseline and continued treatment at 13 or 26 weeks (equivalent to 'moderate benefit') · adults with fibromyalgia enrolled in EERW studies Pregabalin for pain in fibromyalgia in adults (2016) · Cochrane Headline outcomes only | no estimate extracted | 2 studies · 687 participants | High |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Pregabalin for pain in fibromyalgia in adults 2016 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.